Ptc Therapeutics (PTCT)

Mar 31, 2025, 6:21 PM EDT - 1 day ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PCVX XBI

Mar 28, 2025, 4:30 PM EDT - 4 days ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 28, 2025, 9:31 AM EDT - 4 days ago

PTC Therapeutics Shares Fall After EU Drops Translarna Authorization

Mar 28, 2025, 9:20 AM EDT - 4 days ago

PTC Therapeutics says European Commission will remove muscle disorder drug

Mar 28, 2025, 9:00 AM EDT - 4 days ago

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

Mar 20, 2025, 8:00 AM EDT - 12 days ago

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

Mar 9, 2025, 9:47 AM EDT - 23 days ago

PTC Therapeutics: Upside In Rare Disease Innovation

Feb 27, 2025, 9:41 PM EST - 4 weeks ago

PTC Therapeutics, Inc. (PTCT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 4 weeks ago

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 8:00 AM EST - 5 weeks ago

PTC Therapeutics to Participate in Upcoming Investor Conferences

Feb 19, 2025, 7:00 AM EST - 5 weeks ago

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

Feb 13, 2025, 8:00 AM EST - 6 weeks ago

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 9:00 AM EST - 2 months ago

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 8:00 AM EST - 3 months ago

PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 19, 2024, 8:00 AM EST - 3 months ago

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

Dec 2, 2024, 1:50 PM EST - 4 months ago

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Dec 2, 2024, 12:58 PM EST - 4 months ago

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

NVS

Dec 2, 2024, 7:14 AM EST - 4 months ago

PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis

NVS

Dec 2, 2024, 7:00 AM EST - 4 months ago

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

NVS

Nov 27, 2024, 7:51 AM EST - 4 months ago

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs

Nov 27, 2024, 7:00 AM EST - 4 months ago

PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million

Nov 26, 2024, 4:41 PM EST - 4 months ago

PTC Therapeutics discontinues development of ALS drug after trial failure

Nov 26, 2024, 4:30 PM EST - 4 months ago

PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients

Nov 13, 2024, 6:09 PM EST - 4 months ago

US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder

Nov 13, 2024, 6:02 PM EST - 4 months ago

PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy

Nov 7, 2024, 11:19 PM EST - 5 months ago

PTC Therapeutics, Inc. (PTCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 5 months ago

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:30 PM EST - 5 months ago

PTC Therapeutics to Participate at Upcoming Investor Conferences

Oct 30, 2024, 7:00 AM EDT - 5 months ago

PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission

Oct 24, 2024, 7:00 AM EDT - 5 months ago

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results

Oct 18, 2024, 6:30 AM EDT - 5 months ago

CHMP Maintains Negative Opinion on Translarna™ Reexamination

Oct 14, 2024, 4:30 PM EDT - 6 months ago

PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results

Oct 8, 2024, 8:00 AM EDT - 6 months ago

PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program

Oct 1, 2024, 9:00 AM EDT - 6 months ago

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

Sep 26, 2024, 8:00 AM EDT - 6 months ago

FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program

Sep 12, 2024, 4:13 PM EDT - 7 months ago

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Aug 9, 2024, 11:53 AM EDT - 8 months ago

PTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 8 months ago

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 8:00 AM EDT - 8 months ago

PTC Therapeutics Announces Sepiapterin NDA Submission to FDA

Jul 25, 2024, 4:30 PM EDT - 8 months ago

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Jul 15, 2024, 2:00 PM EDT - 9 months ago

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Jun 28, 2024, 6:00 AM EDT - 9 months ago

CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review

Jun 20, 2024, 6:30 AM EDT - 10 months ago

Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients

May 29, 2024, 8:00 AM EDT - 10 months ago

PTC Therapeutics to Participate at Upcoming Investor Conference